EBS - Emergent BioSolutions Inc.
Close
8.38
-0.040 -0.477%
Share volume: 13,861
Last Updated: Thu 26 Dec 2024 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$8.42
-0.04
-0.48%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-02 | 2022-11-09 | 2023-03-01 | 2023-05-10 | 2023-08-09 | 2023-12-11 | 2024-03-08 | 2024-05-02 | |
| Total revenue | 242.700 M | 240.000 M | 330.700 M | 165.100 M | 337.900 M | 270.500 M | 275.800 M | 300.400 M | |
| Cost of revenue | 169.800 M | 148.600 M | 219.400 M | 155.100 M | 190.600 M | 176.800 M | 182.900 M | 144.600 M | |
| Gross profit | 72.900 M | 91.400 M | 111.300 M | 10.000 M | 147.300 M | 93.700 M | 92.900 M | 155.800 M | |
| 25.38% | 21.77% | -91.02% | 1,373.00% | -36.39% | -0.85% | 67.71% | |||
| Operating expenses | 130.900 M | 119.400 M | 151.800 M | 141.100 M | 117.400 M | 101.300 M | 120.000 M | 99.800 M | |
| Selling general and admin | 81.100 M | 80.200 M | 94.200 M | 100.500 M | 91.400 M | 86.000 M | 90.500 M | 84.700 M | |
| Research and development | 49.800 M | 39.200 M | 57.600 M | 40.600 M | 26.000 M | 15.300 M | 29.500 M | 15.100 M | |
| Total expenses | 314.700 M | 282.000 M | 389.100 M | 313.200 M | 324.100 M | 294.400 M | 319.100 M | 260.600 M | |
| -10.39% | 37.98% | -19.51% | 3.48% | -9.16% | 8.39% | -18.33% | |||
| Operating income | -72.000 M | -42.000 M | -58.400 M | -148.100 M | 13.800 M | -23.900 M | -43.300 M | 39.800 M | |
| Ebit | -72.000 M | -42.000 M | -58.400 M | -148.100 M | 13.800 M | -23.900 M | -43.300 M | 39.800 M | |
| Pretax income | -82.800 M | -63.900 M | -71.200 M | -161.100 M | -250.200 M | -265.900 M | -54.000 M | 12.100 M | |
| -22.83% | 11.42% | 126.26% | 55.31% | 6.27% | -79.69% | -122.41% | |||
| Income tax | -26.400 M | 11.800 M | 16.800 M | 21.900 M | 11.100 M | -2.500 M | -1.200 M | 3.100 M | |
| Net income basic | -56.400 M | -75.700 M | -88.000 M | -183.000 M | -261.300 M | -263.400 M | -52.800 M | 9.000 M | |
| -34.22% | -16.25% | -107.95% | -42.79% | -0.80% | 79.95% | 117.05% | |||
| Net income | -56.400 M | -75.700 M | -88.000 M | -183.000 M | -261.300 M | -263.400 M | -52.800 M | 9.000 M | |
| -34.22% | -16.25% | -107.95% | -42.79% | -0.80% | 79.95% | 117.05% |